Immunome (NASDAQ:IMNM) Rating Lowered to Sell at Wall Street Zen

Immunome (NASDAQ:IMNM) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Several other research analysts also recently issued reports on the company. Guggenheim upped their target price on Immunome from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Evercore raised their price target on Immunome from $18.00 to $40.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 16th. Wedbush reissued an “outperform” rating and issued a $31.00 price target on shares of Immunome in a report on Thursday, January 15th. Stephens reduced their price objective on Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research report on Thursday, January 22nd. Eleven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $32.33.

Immunome Trading Up 0.4%

Shares of IMNM opened at $21.04 on Friday. The stock has a market cap of $2.38 billion, a P/E ratio of -8.69 and a beta of 2.12. The company has a 50-day moving average of $22.74 and a two-hundred day moving average of $17.79. Immunome has a 12-month low of $5.15 and a 12-month high of $27.65.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.10). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 57.61%. As a group, analysts forecast that Immunome will post -2.21 EPS for the current fiscal year.

Insider Activity at Immunome

In other news, insider Philip Tsai bought 10,000 shares of the stock in a transaction on Friday, December 19th. The stock was purchased at an average cost of $20.49 per share, with a total value of $204,900.00. Following the purchase, the insider owned 43,300 shares of the company’s stock, valued at approximately $887,217. The trade was a 30.03% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, CEO Clay B. Siegall purchased 46,511 shares of the business’s stock in a transaction on Thursday, December 18th. The stock was acquired at an average price of $21.50 per share, with a total value of $999,986.50. Following the completion of the acquisition, the chief executive officer directly owned 853,247 shares in the company, valued at $18,344,810.50. The trade was a 5.77% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have bought 68,518 shares of company stock valued at $1,453,958. Company insiders own 7.69% of the company’s stock.

Institutional Investors Weigh In On Immunome

Several hedge funds have recently made changes to their positions in the business. Strs Ohio purchased a new stake in shares of Immunome in the fourth quarter valued at $64,000. Assetmark Inc. purchased a new position in Immunome during the third quarter worth about $39,000. Aster Capital Management DIFC Ltd purchased a new position in Immunome during the fourth quarter worth about $121,000. BIT Capital GmbH acquired a new stake in Immunome in the 3rd quarter worth about $69,000. Finally, BNP Paribas Financial Markets boosted its stake in Immunome by 81.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after buying an additional 2,909 shares during the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

More Immunome News

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: HC Wainwright raised multiple 2026 quarterly EPS forecasts (Q1: from ($0.68) to ($0.53); Q2: ($0.70) to ($0.55); Q3: ($0.72) to ($0.56); Q4: ($0.68) to ($0.58)) and lifted FY2026 estimate to ($2.21) from ($2.78). These narrower loss projections suggest better near‑term operating performance. Article Link
• Positive Sentiment: HC Wainwright also boosted FY2027 (from ($2.20) to ($1.81)) and FY2028 (from ($0.79) to ($0.54)) estimates, implying a faster path toward profitability than previously modeled — a material positive for valuation assumptions. Article Link
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $40 price target while raising FY2029 and FY2030 profit forecasts (FY2029: $0.69 from $0.63; FY2030: $1.35 from $1.28), reinforcing a bullish long‑term view that likely helped buying interest. Article Link
• Neutral Sentiment: Despite the upgrades, HC Wainwright still models losses through FY2028 (FY2026 consensus remains around ($2.21)), so the company is viewed as a longer‑duration growth/turnaround investment rather than near‑term profitable. Article Link

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.